Clinical trials
Observational Postoperative Pain trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 3 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 5 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Unknown status | 12 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 6 |
| University of Trieste | 3 |
| University of Roma La Sapienza | 2 |
| A.O.U. Città della Salute e della Scienza | 1 |
| Azienda Ospedaliero, Universitaria Pisana | 1 |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 1 |
| European Society of Anaesthesiology | 1 |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1 |
| Giuliano Marchetti | 1 |
| Humanitas Clinical and Research Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Postoperative Pain | 29 |
| Agnosia | 5 |
| Pain | 3 |
| Breast Neoplasms | 2 |
| Chronic Pain | 2 |
| Hernia, Inguinal | 2 |
| Lung Neoplasms | 2 |
| Acute Pain | 1 |
| Craniosynostoses | 1 |
| Endometrial Neoplasms | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.